Initial safety, tolerability, pharmacodynamics, and pharmacokinetics of Cl-1007 in patients with schizophrenia

Psychopharmacology Bulletin

Volumn 34, Issue 1, 1998, Pages 93-99

  Sramek, John J ^a   Eldon, Michael A ^b   Posvar, Edward L ^b   Feng, Meihua R ^b   Jhee, Stanford S ^a   Hourani, Jameel ^a   Sedman, Allen J ^b   Cutler, Neal R ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b PFIZER INC   (United States)

Author keywords

Cl 1007; Dopamine autoreceptor agonist; Pharmacodynamics; Pharmacokinetics; Safety

Indexed keywords

1,2,3,6 TETRAHYDRO 4 PHENYL 1 [(3 PHENYL 3 CYCLOHEXEN 1 YL)METHYL]PYRIDINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL STRUCTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; SCHIZOPHRENIA; VOMITING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 0031901331     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Altar, CA; Boyar, WC; Oei, E; and Wood, PL. Dopamine autoreceptors modulate the in vivo release of dopamine in the frontal, cingulate, and entorhinal cortices. J. Pharmacol. Exp. Ther. 242(1):115-120, 1987.
2. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: The Association, 1994.
3. Baldessarini, RJ; Campbell, A; Yeghiayan, S; and Neumeyer, JL. Limbic-selective antidopaminergic effects of S(+)-aporphines compared to typical and atypical antipsychotic agents in the rat. In: Racagni, G; Brunello, N; and Fukuda, T, eds. Biological Psychiatry, Vol. 2. Amsterdam: Elsevier, 1991. pp. 837-840.
4. 2 receptor mRNA. Brain Res. 564(2):203-219, 1991.
5. 2 agonist activity in the rat. Brain Res. 592:348-352, 1992.
6. Campbell, A; Yeghiayan, S; Baldessarini, RJ; and Neumeyer, JL. Selective antidopaminergic effects of S(+)N-n-propylnoraporphines in limbic versus extrapyramidal sites in rat brain: Comparisons with typical and atypical antipsychotic agents. Psychopharmacology (Berlin) 103:323-329, 1991.
7. Cutler, NR; Murphy, MF; Nash, RJ; Prior, PL; and DeLuna, DM. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1, 2, 3, 4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: Preliminary findings. J. Clin. Pharmacol. 30(6):556-561, 1990.
8. Cutler, NR, and Sramek, JJ. Scientific and ethical concerns in clinical trials in Alzheimer's patients: The bridging study. Eur. J. Clin. Pharmacol. 48(6):421-428, 1995a.
9. Cutler, NR, and Sramek, JJ. The bridging concept: Optimizing dose for Phase II/III in Alzheimer's disease. Neurodegeneration 5(4):511-514, 1996.
10. Cutler, NR, and Sramek, JJ. The target population in Phase I clinical trials of cholinergic compounds in Alzheimer's disease: The role of the "bridging study." Alzheim. Dis. Assoc. Disord. 9(3):139-145, 1995b.
11. Davis, KL; Kahn, RS; Ko, G; and Davidson, M. Dopamine in schizophrenia: A review and reconceptualization. Am. J. Psychiatry 148(11):1474-1486, 1991.
12. Eldon, MA; Underwood, BA; Posvar, EL; Feng, R; Wright, DS; and Sedman, AJ. Safety, tolerance, and pharmacodynamics of CI-1007, a new dopamine autoreceptor agonist, in healthy subjects. Clin. Pharmacol. Ther. 61:176, 1997.
13. Feng, MR; Corbin, AE; Wang, Y; Christoffersen, CL; Wiley, JN; Strenkoski, CA; Tucker, EV; Ninteman, FW; Meltzer, LT; Heffner, TG; and Wright, DS. Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. Pharm. Res. 14(3):329-336, 1997.
14. 2 dopamine receptor subtype mRNA levels in the brain. FEBS Lett. 339(1-2):63-66, 1994.
15. Fox, CA; Mansour, A; and Watson, SJ Jr. The effects of haloperidol on dopamine receptor gene expression. Exp. Neurol. 130(2):288-303, 1994.
16. Kasper, S; Fuger, J; Zinner, HJ; Bauml, J; and Moller, HJ. Early clinical results with the neuroleptic roxindole (EMD 49,980) in the treatment of schizophrenia: An open study. Eur. Neuropsychopharmacol. 2(1):91-95, 1992.
17. Kay, SR, and Opler, LA. L-dopa in the treatment of negative symptoms: A single-subject experimental study. Int. J. Psychiatry Med. 15(3):293-298, 1985.
18. Kleinbloesem, CH; Jaquet-Muller, F; al-Hamdan, Y; Baldauf, C; Gisclon, L; Wesnes, K; Curtin, CR; Stubbs, RJ; Walker, SA; and Brunner-Ferber, F. Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men. Clin. Pharmacol. Ther. 59(6):675-685, 1996.
19. Krause, W; Mager, T; Kuhne, G; Duka, T; and Voet, B. The pharmacokinetics and pharmacodynamics of lisuride in healthy volunteers after intravenous, intramuscular, and subcutaneous injection. Eur. J. Clin. Pharmacol. 40(4):399-403, 1991.
20. Lahlou, S, and Demenge, P. Contribution of spinal dopamine receptors to the hypotensive action of bromocriptine in rats. J. Cardiovasc. Pharmacol. 18(3):317-325, 1991.
21. 2-family receptor distribution in human postmortem tissue: An autoradiographic study. Neuroreport 6(18):2505-2512, 1995.
22. 3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. USA 89(17):8155-8159, 1992.
23. Lindenmayer, JP. New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatr. Scand. (Suppl.) 388:15-19, 1995.
24. Meltzer, HY. Dopamine autoreceptor stimulation: Clinical significance. Pharmacol. Biochem. Behav. 17(Suppl. 1):1-10, 1982.
25. Meltzer, HY. Relevance of dopamine autoreceptors for psychiatry: Preclinical and clinical studies. Schizophr. Bull. 6(3):456-475, 1980.
26. Meltzer, LT; Christoffersen, CL; Corbin, AE; Ninteman, FW; Serpa, KA; Wiley, JN; Wise, LD; and Heffner, TG. CI-1007, a dopamine partial agonist and potential antipsychotic agent: II. Neurophysiological and behavioral effects. J. Pharmacol. Exp. Ther. 274(2):912-920, 1995.
27. Miller, AL; Maas, JW; Contreras, S; Seleshi, E; True, JE; Bowden, C; and Castiglioni, J. Acute effects of neuroleptics on unmedicated schizophrenic patients and controls. Biol. Psychiatry 34(3):178-187, 1993.
28. 2 agonist, in the treatment of negative symptoms of chronic schizophrenia. Biol. Psychiatry 33(10):687-693, 1993.
29. 1 receptors in schizophrenia revealed by PET. Nature 385(6617):634-636, 1997.
30. Okuma, T. Differential sensitivity to the effects of psychotropic drugs: Psychotics vs. normals; Asian vs. Western populations. Folia Psychiatr. Neurol. Jpn. 35(1):79-87, 1981.
31. 2 receptor agonists and antagonists. J. Cardiovasc. Pharmacol. 18(4):548-555, 1991.
32. Pugsley, TA; Davis, MD; Akunne, HC; Cooke, LW; Whetzel, SZ; MacKenzie, RG; Shih, YH; van Leeuwen, DH; DeMattos, SB; Georgic, LM; et al. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects. J. Pharmacol. Exp. Ther. 274(2):898-911, 1995.
33. Puri, SK; Ho, I; Hsu, R; and Lassman, HB. Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: A potential therapeutic agent for Alzheimer's disease. J. Clin. Pharmacol. 30(10):948-955, 1990.
34. Sedvall, G, and Farde, L. Chemical brain anatomy in schizophrenia. Lancet 346(8977):743-749, 1995.
35. Simpson, GM; Pi, E; and Sramek, JJ. Neuroleptics and antipsychotics. In: Dukes, MNG, ed. Meyler's Side Effects of Drugs, 13th ed. Amsterdam: Elsevier, 1996. pp. 117-135.
36. 3) as a target for neuroleptics. Nature 347(6289):146-151, 1990.
37. Sramek, JJ; Cutler, NR; Kurtz, NM; Murphy, MF; and Carta, A. Optimizing the Development of Antipsychotic Drugs. Chichester, England: Wiley, 1997.
38. Sramek, JJ; Fresquet, A; Marion-Landais, G; Hourani, J; Jhee, SS; Martinez, L; Jensen, CM; Bolles, K; Carrington, AT; and Cutler, NR. Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: A bridging study. J. Clin. Psychopharmacol. 16(6):454-458, 1996.
39. Sramek, JJ; Herrera, J; Costa, J; and Heh, C. Persistence of plasma neuroleptic levels after drug discontinuation. J. Clin. Psychopharmacol. 7(6):436-437, 1987.
40. Sramek, JJ; Hurley, DJ; Wardle, TS; Satterwhite, JH; Hourani, J; Dies, F; and Cutler, NR. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J. Clin. Pharmacol. 35(8):800-806, 1995a.
41. Sramek, JJ; Sedman, AJ; Reece, PA; Hourani, J; Bockbrader, H; and Cutler, NR. Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci. 57(5):503-510, 1995b.
42. Wetzel, H; Hillert, A; Grunder, G; and Benkert, O. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. Am. J. Psychiatry 151(10):1499-1502, 1994.
43. White, FJ, and Wang, RY. A10 dopamine neurons: Role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. Life Sci. 34(12):1161-1170, 1984.
44. Wiedemann, K; Benkert, O; and Holsboer, F. B-HT 920, a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia. Pharmacopsychiatry 23(1):50-55, 1990.
45. Wiedemann, K, and Kellner, M. Endocrine characterization of the new dopamine autoreceptor agonist roxindole. Exp. Clin. Endocrinol. 102(4):284-288, 1994.